Sorry, you need to enable JavaScript to visit this website.

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1
(PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors

Category & Conditions: Cancer
Medicine: ARRY-382 (PF-07265804)
ClinicalTrials.gov Identifier (NCT): NCT02880371
Protocol ID: C4261001
    Share
PrintDownload
Open Plain Language Summary Result: Click here